Related references
Note: Only part of the references are listed.Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study
S. Sha et al.
DIABETES OBESITY & METABOLISM (2015)
Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants
Damayanthi Devineni et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2015)
The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats
Takahiro Oguma et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
SGLT2 inhibitors: their potential reduction in blood pressure
George Maliha et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
Nobuya Inagaki et al.
JOURNAL OF DIABETES INVESTIGATION (2015)
Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
Nobuya Inagaki et al.
CLINICAL DRUG INVESTIGATION (2014)
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
S. Sha et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of canagliflozin rnonotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
Nobuya Inagaki et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes (vol 9, e105638, 2014)
S. Sha et al.
PLOS ONE (2014)
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
Yoshihito Fujita et al.
JOURNAL OF DIABETES INVESTIGATION (2014)
Analysis of the Effect of Canagliflozin on Renal Glucose Reabsorption and Progression of Hyperglycemia in Zucker Diabetic Fatty Rats
Chiaki Kuriyama et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
N. Inagaki et al.
DIABETES OBESITY & METABOLISM (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
David Polidori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
Damayanthi Devineni et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
D. Devineni et al.
DIABETES OBESITY & METABOLISM (2012)
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
J. E. Gerich
DIABETIC MEDICINE (2010)
Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Sumihiro Nomura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes - results of a hyperglycaemic glucose clamp study
Klaus Rave et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Share Paper
